You searched for "ARN"
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...New NHS study highlights ways to help patients with painful, slow-healing corneal wounds recover sooner
Teams at Queen Victoria Hospital NHS Foundation Trust (QVH) and Maidstone and Tunbridge Wells NHS Trust (MTW) have published new findings highlighting how long and demanding treatment can be for people with persistent corneal epithelial defects and how a clinic-based...The Sickle Cell Retinopathy Network is leading global change in screening and management
Sickle cell disease or disorder (SCD) is one of the most neglected health conditions in the world. A strong hypothesis is that this is because SCD affects people of African, Caribbean and other Global Majority communities and has received disproportionately...
A phase 3 randomised trial of nicotinamide for skin cancer chemoprevention
To B3, or not to B3? That was the question asked in this controlled trial in which the authors were able to show that oral nicotinamide (vitamin B3) is able to reduce further skin cancer development in high risk patients....
A randomised, controlled trial of oral propranolol in infantile haemangioma
Since its use was first reported in the New England Journal in 2008, propranolol has become the preferred treatment for infantile haemangiomas. However, there is no consensus as to the optimum dose or duration of treatment and there is a...
Inhibiting high-risk corneal allografts
The cornea is an immune privileged site and as such corneal transplants are very successful. However, in situations where this privilege is lost the failure rises substantially. To combat rejection inhibition of the immune responses depends on steroids and other...
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...
